EUCTR2018-001417-32-FR进行中（未招募）1 期
ong-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation
CHU-Hôpitaux de Rouen0 个研究点目标入组 77 人开始时间: 2018年6月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient included in RITXIMAB3 study
- •Patient having read and understood the information letter and signed the Informed Consent Form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 17
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Person deprived of liberty by administrative or judicial decision
- •Person placed under judicial protection
- •Person under guardianship or supervision
- •Women pregnant or lactating
研究者
相似试验
进行中（未招募）
1 期
ong term follow-up clinical trial to the MUST trial which investigates which treatment of systemic steroid treatment and a steroid implant which is inserted into the eye gives the best visual outcome for patients with chronic eye inflammation.EUCTR2011-001078-25-GBational Institute of Health, National Eye Institute250
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15
进行中（未招募）
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200
进行中（未招募）
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864EUCTR2016-000297-38-FRInstitut de Recherches Internationales Servier (I.R.I.S)200